Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG daily Stock Chart
Novartis AG
Index- P/E27.47 EPS (ttm)2.80 Insider Own9.30% Shs Outstand2.58B Perf Week2.25%
Market Cap198.27B Forward P/E14.70 EPS next Y5.23 Insider Trans0.04% Shs Float2.53B Perf Month9.57%
Income6.71B PEG5.45 EPS next Q1.17 Inst Own10.70% Short Float0.25% Perf Quarter8.79%
Sales49.44B P/S4.01 EPS this Y-2.80% Inst Trans4.66% Short Ratio1.88 Perf Half Y-5.50%
Book/sh31.55 P/B2.44 EPS next Y10.15% ROA5.10% Target Price91.20 Perf Year8.41%
Cash/sh3.01 P/C25.49 EPS next 5Y5.04% ROE9.10% 52W Range66.93 - 83.58 Perf YTD5.51%
Dividend2.75 P/FCF93.48 EPS past 5Y-5.80% ROI7.30% 52W High-8.05% Beta0.77
Dividend %3.58% Quick Ratio0.80 Sales past 5Y-3.60% Gross Margin65.10% 52W Low14.82% ATR0.85
Employees118393 Current Ratio1.10 Sales Q/Q-1.50% Oper. Margin16.40% RSI (14)71.63 Volatility1.09% 1.04%
OptionableYes Debt/Eq0.32 EPS Q/Q-8.00% Profit Margin13.60% Rel Volume1.18 Prev Close77.04
ShortableYes LT Debt/Eq0.24 EarningsJan 25 BMO Payout96.30% Avg Volume3.38M Price76.85
Recom2.00 SMA203.61% SMA505.64% SMA2000.38% Volume3,981,486 Change-0.25%
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Apr-12-16Downgrade Morgan Stanley Equal-Weight → Underweight
Mar-23-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Feb-22-17 03:01PM  In 'groundbreaking' deal, Harvard Pilgrim negotiates contracts to save on two pricey drugs at
10:37AM  Keytruda: Mercks Immuno-Oncology Blockbuster Drug
Feb-21-17 12:37PM  Momenta, Pfizer Give Teva Pharma Breathing Room On Generic MS Drug
12:26PM  Why Momenta Pharmaceuticals, Inc. Shares Got Crushed Today at Motley Fool
Feb-20-17 07:37AM  This Keeps Driving Sanofis Growth
Feb-18-17 12:09PM  2 High-Yield Dividend Stocks That Are Ridiculously Cheap at Motley Fool
Feb-17-17 04:46PM  Inside Sanofis Revenues in 4Q16
08:15AM  Blog Coverage Ionis Pharma Closed on its Collaboration Agreement with Novartis Following Clearance under the Hart-Scott-Rodino Antitrust Improvements Act Accesswire
07:37AM  Prolia Expected to Be a Significant Growth Driver for Amgen in 2017
Feb-16-17 09:27AM  Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback
09:05AM  GlaxoSmithKlines Valuation Compared to Its Peers
Feb-15-17 12:38PM  Bristol-Myers: Don't Bet on a Pfizer Acquisition at
Feb-14-17 03:33PM  Bristol-Myers Squibb: Takeover Target? at
01:35PM  4Q16 Performance of GlaxoSmithKlines Business Segments
11:13AM  Novartis AG (ADR) (NVS) Greater Use Of Technology In Transforming Medical Education at Insider Monkey
02:00AM  These N.Y.C.-area doctors received the most payments from drug and device makers at
Feb-10-17 04:10PM  Intercept Bounds To 3-Month High On NASH Trial Edits; Analysts Split
10:43AM  10 Most Diverse Companies In The US at Insider Monkey
08:22AM  Is Array BioPharma the Best Clinical-Stage Biotech Stock to Buy in 2017? at Motley Fool
Feb-09-17 10:15AM  UBS Makes First Big 2017 Addition to Dividend Rulers Stocks List
Feb-08-17 06:00AM  Propeller Health Enters into Collaboration to Connect Breezhaler Devices to the Propeller Platform PR Newswire
Feb-03-17 10:36AM  Novartiss Valuation after the 4Q16 Results
09:06AM  Why the Majority of Analysts Deem Novartis a Buy
07:36AM  Novartiss Financial Guidance and Priorities for 2017
Feb-02-17 10:37AM  Novartiss Recent Developments
09:49AM  Novartis (NVS) Votubia Gets EU Approval for Label Expansion
09:07AM  Inside Novartiss Eye Care Performance in 4Q16
07:37AM  Inside Novartiss Generics Performance in 4Q16
06:42AM  GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?
Feb-01-17 05:20PM  Novartis Has Bright Future
04:35PM  Novartiss Innovative Medicines Segment in 4Q16
03:05PM  Weighing the Foreign Exchange Impact on Novartiss Revenues in 4Q16
01:19PM  Novartiss 4Q16 Earnings Meet Analysts Estimates
12:24PM  Roche CEO Shrugs Off Trump's Drug Stance; 2016 Sales Narrowly Miss
11:20AM  Waltham-based cancer drug firm Cerulean Pharma may seek a buyer at
07:14AM  Drug Stocks Rally on Trump Meet with Pharma Bigwigs
Jan-31-17 01:03PM  Why Momenta Pharmaceuticals, Inc. Stock Skyrocketed Higher Today at Motley Fool
11:47AM  Novartis Considers Alcon Spin-Off at Forbes
11:20AM  Novartis Anti-Seizure Drug Votubia Wins EU Nod at Investopedia
10:33AM  Trump pushes drugmakers for lower prices, more U.S. production Reuters
09:55AM  Incyte and Calithera Enter into Deal for Oncology Candidate
05:45AM  Novartis CEO to meet Trump along other drug industry executives Reuters
05:41AM  Novartis CEO to meet Trump along other drug industry execs Reuters
Jan-30-17 04:32PM  I-O Players Incyte, Roche Squeeze Array's Melanoma Market: Leerink
04:18PM  Regeneron, Sanofi Could Appease LDL-Frustrated Buyers On Eczema Drug
03:18PM  Mallinckrodt Divests Drug Delivery Unit as Shedding Continues
03:12PM  Novartis Withdraws Amgen Biosimilar Application at Investopedia
09:06AM  Exploring JNJs 2017 Profitability and Financial Guidance
07:34AM  Amgen Wins Favorable CHMP Opinion for Humira Biosimilar
01:00AM  Novartis Signals Growing Ambitions for CAR-T Cancer Treatments at Bloomberg
Jan-29-17 08:08AM  Guess Who Can't Wait for Trumpcare? (Hint: It's Not the Consumer) at Motley Fool
Jan-26-17 12:52PM  Moody's puts Novartis on notice over debt-funded buyback plan Reuters
11:23AM  Amgens Enbrel Safe from Copycat Challenge for Now at Investopedia
11:14AM  Novartis AG -- Moody's changes outlook on Novartis' Aa3 rating to negative on share buy backs announcement; affirms ratings at Moody's
09:28AM  11 Largest Pharmaceutical Companies In The World at Insider Monkey
08:15AM  Blog Coverage Novartis Announced Buyback of Shares Worth $5 Billion; Considers Strategic Options for Alcon Division Accesswire
06:02AM  GM, Nike, Microsoft Are Hot Now That Dow Has Hit 20,000
12:48AM  [$$] Novartis Weighs Spinoff of Alcon Eye-Care Business at The Wall Street Journal
Jan-25-17 04:21PM  Incyte Gets $112 Million Boost On Novartis Jakavi Royalties: RBC
02:52PM  Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug
12:05PM  Why Eli Lilly Expects to See Revenue Growth in 4Q16
11:52AM  European markets close higher on earnings; Logitech up 15%; Deutsche Bank rises 5% at CNBC
11:30AM  [$$] Novartis: buying time at Financial Times
10:48AM  Novartis May Spin Off Struggling Alcon Eye Unit at Investopedia
10:20AM  Novartis Tries to Cure Its Eye Strain at Bloomberg
09:30AM  [$$] Novartis launches $5bn share buyback as it eyes Alcon spin-off at Financial Times
09:07AM  Behind Amgens Plans to Expand in Neuroscience in 2017
08:45AM  Novartis (NVS) Beats Q4 Earnings, Might Spin-Off Alcon
07:44AM  Positive Earnings Are Setting Up the Dow for Its Push to 20,000
07:39AM  Novartis says court battle will delay its Enbrel copy until 2018 at least
07:12AM  5 Things You Must Know Before the Market Opens Wednesday
06:30AM  Novartis launches $5 bln share buyback, mulls Alcon spin-off Reuters
05:59AM  Alcon, Once Gem Worth Over $50 Billion, Weighs on Novartis at Bloomberg
05:40AM  Novartis beats 4Q profit forecasts
03:24AM  Drug firm Novartis mulls options for Alcon amid flat 4Q net
03:21AM  [$$] Novartis May Spin Off Alcon at The Wall Street Journal
03:21AM  Novartis Misses Q4 Earnings Estimate, Mulls Alcon Spin-Off
03:16AM  Novartis chases rivals with next wave of cancer immunotherapy Reuters
02:42AM  Were looking at all options for struggling eye care business, says Novartis CEO at CNBC
01:32AM  Novartis Mulls Options Including Spinoff, IPO for Eye-Care Unit
01:09AM  Novartis: Looking at whats best for shareholders on Alco...
01:09AM  Novartis CEO: There'll be more consolidation in sector to...
Jan-24-17 09:06AM  Recent Developments at Novartis
07:38AM  Bristol-Myers Squibbs 4Q16 Estimates: Expect Growth!
07:36AM  Novartiss 4Q16 Estimates: Expectations from Alcon
Jan-23-17 05:27PM  Better Buy: Exelixis, Inc. vs. Novartis at Motley Fool
10:37AM  Novartiss 4Q16 Estimates: How Could Sandoz Perform?
09:07AM  Novartiss 4Q16 Estimates: Innovative Medicines Segment
07:38AM  Analysts Expect Negative Growth for Novartis in 4Q16
Jan-20-17 05:41PM  Novartiss 4Q16 Earnings: What Is Expected?
02:52PM  Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?
02:15AM  Novartis CEO: Trump Understands Value of Drug Innovation at Bloomberg
Jan-19-17 01:02AM  CSL shares jump on profit upgrade AAP
Jan-18-17 06:33PM  CSL shares rally on profit guidance hike AAP
06:01PM  Mallinckrodt Hit With $100M Fine for Squelching Rival to Infant Seizure Drug
04:13PM  Mallinckrodt Dives, Rebounds, Retreats On FTC Drug Price Settlement
04:01PM  Mallinkrodt Shares Tank Despite $100 Million FTC Deal
06:56AM  Novartis CEO Discusses Impact of Trump on Drug Industry at MarketWatch
Jan-17-17 09:59AM  Why Bristol-Myers Squibb May Be a Merger Target Soon
07:37AM  How Did Novartiss Innovative Medicines Segment Perform?
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Innovative Medicines, Sandoz, and Alcon. The Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. It franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies. The Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The Alcon segment offers eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses for use in surgical procedures to treat cataracts, vitreoretinal conditions, glaucoma, and refractive errors; and contact lenses and lens care products. The company has collaboration and licensing agreements with Xencor for the development of bispecific antibodies for treating cancer; and with Surface Oncology to access four pre-clinical programs in immuno-oncology. It also has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and Caribou Biosciences for the development of drug discovery tools. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerOct 31Buy13.0084,6151,099,9952,545,652Oct 31 04:50 PM
Novartis Bioventures Ltd10% OwnerOct 31Sale13.003394,40762,575Oct 31 04:50 PM
Novartis Institutes for BioMed10% OwnerMay 11Buy18.00277,7774,999,9865,573,658May 11 06:57 PM
Novartis Bioventures Ltd10% OwnerApr 12Buy10.00300,0003,000,0002,310,924Apr 12 05:09 PM